Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nevertheless, ClC-3 knockdown had little effect on ROS levels, indicating that ROS acted upstream of ClC-3 and that both ROS and ClC-3 participated in EBSS-induced autophagy regulation in CNE-2Z.
|
30992317 |
2019 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we showed that the involvement of ClC-3 chloride channel in the selective cytotoxicity of DSF/Cu<sup>2+</sup> in the poorly-differentiated nasopharyngeal carcinoma.
|
31606620 |
2019 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrated that the selective antitumor activities of DHA in NPC may occur through the specific activation of the CLC-3 Cl<sup>-</sup> channel, leading to Cl<sup>-</sup> efflux, and induced AVD, then led to [Ca<sup>2+</sup> ]<sub>i</sub> accumulation and caspase-3 activation, and finally induced apoptosis.
|
30171707 |
2018 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously reported that AQP-3 aquaglyceroporin and ClC-3 chloride channels could form complexes to regulate cell volume in nasopharyngeal carcinoma cells.
|
26794461 |
2016 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AQP-3 water channel and the ClC-3 chloride channel coordinate the hypotonicity-induced swelling volume in nasopharyngeal carcinoma cells.
|
25450461 |
2014 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ClC-3 chloride channel protein is a downstream target of cyclin D1 in nasopharyngeal carcinoma cells.
|
23270726 |
2013 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ClC-3 protein may be considered as a potential tumor marker and therapeutic target for human nasopharyngeal carcinoma.
|
22108225 |
2012 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ClC-3 is a candidate of the channel proteins that mediate or regulate the acid-activated chloride current in nasopharyngeal carcinoma cells.
|
22496242 |
2012 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
ClC-3 protein may be considered as a potential tumor marker and therapeutic target for human nasopharyngeal carcinoma.
|
22108225 |
2012 |
Nasopharyngeal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ClC-3 is a main component of background chloride channels activated under isotonic conditions by autocrine ATP in nasopharyngeal carcinoma cells.
|
21792908 |
2011 |
Nasopharyngeal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ClC-3 may regulate CNE-2Z cell migration by modulating cell volume.
|
18359479 |
2008 |
Glioma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study explored the involvement of CLCN3 in cisplatin resistance in human glioma U251 cells.
|
29963152 |
2018 |
Glioma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest CLC-3 promotes the aggressiveness of glioma at least in part through nuclear factor-κB pathway, and might be a novel prognostic biomarker and therapeutic target for glioma.
|
28969029 |
2017 |
Glioma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy.
|
23408563 |
2013 |
Glioma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot.
|
12843258 |
2003 |
Glioma
|
0.340 |
AlteredExpression
|
disease |
LHGDN |
Transcripts for ClC-2 thru ClC-7 were detected in a human glioma cell line by PCR, whereas only ClC-2, ClC-3, and ClC-5 protein could be identified by Western blot.
|
12843258 |
2003 |
Glioma
|
0.340 |
Biomarker
|
disease |
BEFREE |
In the present study we provide several lines of evidence that glioma Cl- currents are primarily mediated by ClC-2 and ClC-3, two genes that belong to the ClC superfamily.
|
12843258 |
2003 |
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms by which CLC-3 is regulated in GC are unclear.
|
30217218 |
2018 |
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment.
|
29795988 |
2018 |
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
mixed gliomas
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of voltage-gated chloride channels in human glioma cells.
|
12843258 |
2003 |
Malignant Glioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression of voltage-gated chloride channels in human glioma cells.
|
12843258 |
2003 |